Navigation Links
Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Date:11/11/2010

SAN DIEGO, Nov. 11, 2010 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) will host investors and analysts in New York City on November 18, 2010 for an in depth discussion on the current management of Clostridium difficile infection and the market opportunity for fidaxomicin.  A live webcast of the event beginning at 9:00 a.m. ET will be accessible on the Investors page of the Company's website at www.optimerpharma.com. A replay will be available for 90 days.

The program will feature presentations by:

  • Mark Miller, M.D., Head of Infectious Diseases Division and Chair of Infection Prevention and Control Committee, SMBD Jewish Hospital in Montreal
  • Pedro Lichtinger, President and CEO, Optimer
  • Sherwood Gorbach, M.D., Chief Medical Officer, Optimer and Professor of Public Health & Medicine, Tufts University School of Medicine

  • (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

    (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

    For additional information regarding this event, please contact Christina Donaghy, Corporate Communications Manager at Optimer Pharmaceuticals, at cdonaghy@optimerpharma.com.

    About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium di
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2

    Related medicine technology :

    1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
    2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
    3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
    4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
    5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
    6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
    7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
    8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
    9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
    10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
    11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2014)... Research and Markets  has announced the addition of the ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... pain in the human body,s joints such as wrists, fingers, ... the tissues that surround the joints and in other organs. ... usually just mild pain around the joints coupled with stiffness ...
    (Date:7/28/2014)... July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... announced today that its new PicoWay® device has received ... and colors and pigmented lesions on any skin type. ... with 532nm and 1064nm wavelengths, which utilizes Syneron,s proprietary ... pulses which are trillionths of a second, known as ...
    (Date:7/28/2014)... Concord Medical Services Holdings Limited ("Concord Medical" ... leading specialty hospital management solution provider and operator of ... in China , today announced that ... a special cash dividend of US$0.30 per ordinary share ... Company,s outstanding ordinary shares. The total expense for the ...
    Breaking Medicine Technology:Global Rheumatoid Arthritis Drugs Market 2014-2018 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4Concord Medical Declares Special Dividend 2
    ... Feb. 14, 2012 Glenveigh Medical  announced today that ... its request for orphan drug designation for a potential ... compound, digoxin immune fab (ovine) , is an ... toxicity. Glenveigh, a nationally renowned life science company, has ...
    ... 14, 2012 ZONARE Medical Systems, Inc., a developer ... of Timothy A. Marcotte to President and Chief Executive ... served as Chief Operating Officer with responsibility for the ... the company,s Chief Financial Officer.  Prior to ZONARE, he ...
    Cached Medicine Technology:Nationally Recognized Glenveigh Medical Announces Orphan Drug Designation for Treatment for Severe Preeclampsia and Eclampsia 2ZONARE Medical Systems Announces Appointment of Timothy A. Marcotte as President and Chief Executive Officer 2
    (Date:7/28/2014)... 28, 2014 Cape Regional Medical ... Exchange technology solution in an effort to ... support collaboration with their New Jersey health information ... center located in New Jersey, serves the local ... a variety of inpatient and outpatient services. With ...
    (Date:7/28/2014)... News) --,The more chronic medical conditions people have at ... a new study claims. Since nearly four ... at Johns Hopkins Bloomberg School of Public Health in ... in life expectancy are slowing in the United States. ... kidney disease and heart failure is now the norm ...
    (Date:7/28/2014)... Steven Reinberg HealthDay Reporter ... have dementia and heart rhythm irregularities are more likely to ... found. In fact, the study of more than 16,000 ... percent more likely to get a pacemaker than those without ... study is why folks with dementia are so much more ...
    (Date:7/28/2014)... Washington, NY (PRWEB) July 28, 2014 Parker ... many years fighting to ensure that the heroes of 9/11 ... Fund (VCF) has announced an important deadline. According to a ... were diagnosed with a covered cancer on or before October ... October 12, 2014. First responders and others who were allegedly ...
    (Date:7/28/2014)... JOLLAWhen you,re expecting somethinglike the meal you,ve ordered ... unique electrical rhythms sweep through your brain. ... they reflect a symphony of cellsboth excitatory and ... role has been debated, gamma waves have been ... the patterns have been tied to schizophrenia, Alzheimer,s ...
    Breaking Medicine News(10 mins):Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 3Health News:Memory relies on astrocytes, the brain's lesser known cells 2Health News:Memory relies on astrocytes, the brain's lesser known cells 3
    ... grant of Rs.190 million ($4.17 million) to prevent the ... agreement to this effect was signed by US Ambassador ... (WHO) representative to India Salim Habayeb. ,The ... India undertake research and implement the national disease control ...
    ... has given GlaxoSmithKline PLC's anti-seizure medicine to treat Primary ... ,According to GlaxoSmithKline, the U.K. pharmaceutical company, the drug, ... and older, as well as adults. ,PGTC ... occurring type of generalized seizures, seen in about 20% ...
    ... Drug Administration takes days to track down the source of ... sensor that can enable growers to do the job themselves ... engineering at Drexel University, has developed an “intelligent” sensor technology ... dollars, the sensor can provide a result within 10 minutes ...
    ... most rural counties of the United States are hospitalized ... //by HHS Agency for Healthcare Research and Quality and ... Ambulatory Pediatrics. ,The study, which was led by ... of health care, health status, and other measures for ...
    ... anthrax attacks in the United States in 2001 had the ... the anthrax used//, belonged to the common variety, though lethal ... into the source of anthrax that reportedly killed five people ... 11 twin tower disaster. ,The Anthrax which claimed ...
    ... The Good Shepherd Medical Center in Oregon is providing healthy ... eating habits.// Foods from wild salmon to local organic foods ... a topping of antioxidant-rich dried cherries. , Angela ... Hermiston, OR for five days recently for the delivery of ...
    Cached Medicine News:Health News:Local Health Care Limited for Rural Children 2
    ... The Gellhorn Pessary is used ... degree prolapse, or procidentia. It ... base and comes in nine ... Gellhorn easily folds over for ...
    ... 450,000 people in,the United States die ... a defibrillation shock,quickly during an episode ... that passes, the chance of,survival decreases ... Association,and JCAHO recommend that AEDs be ...
    ... The BioArc™ System treats female urinary stress ... using either a suprapubic (BioArc™ SP) or ... is an innovative hybrid system combining synthetic ... hybrid sling currently available. The BioArc utilizes ...
    ... Proven tension-free sling technology ... porcine acellular collagen matrix sling, ... tissue-to-tissue contact between sling and ... urethral or vaginal abrasion or ...
    Medicine Products: